Skip to main content
Equibles

Kaouthar Lbiati

CEO

Hepion Pharmaceuticals, Inc. (HEPA)

Board Member

Hepion Pharmaceuticals, Inc. (HEPA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Hepion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get HEPA alerts

About Kaouthar Lbiati

Kaouthar Lbiati is recorded as CEO at Hepion Pharmaceuticals, Inc. (HEPA) since June 16, 2025 and Board Member at Hepion Pharmaceuticals, Inc. (HEPA) since June 27, 2022. Hepion Pharmaceuticals, Inc. reported in an 8-K filed March 18, 2026 that Kaouthar Lbiati resigned as Chief Executive Officer, effective March 16, 2026. Hepion Pharmaceuticals, Inc. reported in an 8-K filed June 9, 2025 that Kaouthar Lbiati was appointed interim Chief Executive Officer, effective June 16, 2025. Hepion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Hepion Pharmaceuticals, Inc. includes Dr. Kaouthar Lbiati (CEO), Gary Stetz (CEO, CFO and Board Member), John Cavan (CEO and CFO) and 7 others.

“On March 16, 2026, Dr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. (the "Company") informed the Board of Directors (the "Board") of the Company that she was resigning as Chief Executive Officer for personal reasons, effective immediately.”
Hepion Pharmaceuticals, Inc. Form 8-K, filed March 18, 2026 · Read the filing
“On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.”
Hepion Pharmaceuticals, Inc. Form 8-K, filed June 9, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Hepion Pharmaceuticals, Inc.

Recent activity